Alnylam Pharmaceuticals: Q4 Earnings Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q4 earnings results on Thursday, February 10, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Alnylam Pharmaceuticals Q4 EPS $(1.69) Misses $(1.54) Estimate, Sales $258.535M Beat $233.62M Estimate
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.54) by 9.74 percent. This is a 5.62 percent decrease over losses of $(1.60) per share from the same period last year.
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell
• Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish.
Guggenheim Upgrades Alnylam Pharmaceuticals to Buy, Announces $170 Price Target
Guggenheim analyst Etzer Darout upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Neutral to Buy and announces $170 price target.
SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $109
SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $108 to $109.
A Bearish Sign Appears On Alnylam Pharmaceuticals’s Chart
If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Alnylam Highlights 18-Month Results From HELIOS-A Phase 3 Study Of Vutrisiran: All Secondary Endpoints Were Met; BZ NOTE: Co. Previously Announced All Primary, Secondary Endpoints Met On 9-Month Basis; However, Release Today Does Not Mention Primary
– Vutrisiran Met All 18 Month Secondary Endpoints, Including Statistically Significant Improvements in Neuropathy Impairment, Quality of Life (QoL), Gait Speed, Nutritional Status and Overall Disability, Relative
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.